- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05928780
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
June 23, 2023 updated by: Zhimin Shao, Fudan University
A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients With Locally Advanced or Metastatic TNBC (Future-Trop2 Study)
To explore the efficacy and safety of TROP2 in the treatment of ABC
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
To explore the efficacy and safety of advanced first-line TROP2 precision therapy in patients with locally advanced or metastatic triple-negative breast cancer based on molecular subtypes
Study Type
Interventional
Enrollment (Estimated)
125
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Women ≥18 years old and ≤70 years old.
- ECOG body status level 0 ~ 1.
- The expected survival is not less than 3 months.
- Breast cancer patients with histologically proven invasive triple-negative breast cancer (specifically defined as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) who are all negative by pathological tests. Specifically: ER negative: IHC<1%, PR negative: IHC<1%, HER2 negative: IHC-/+ or IHC++ but FISH/CISH negative. All specimens should be verified by the pathology department of the research center, and the molecular typing of relapses and metastases should be re-checked.
- Tumor stage: recurrent or metastatic breast cancer; Patients with local recurrence need to be confirmed by the investigator that radical surgical resection is not possible.
- Stage II: patients who have not used paclitaxel or have used paclitaxel in adjuvant/neoadjuvant therapy, but the interval from the end of treatment to relapse is greater than 6 months; No systemic anti-tumor therapy (chemotherapy, targeted therapy, etc.) has been received in the advanced stage.
- Stage I: The advanced stage has received ≥1 line systemic anti-tumor therapy (chemotherapy, targeted therapy, etc.).
- Have at least one measurable lesion or unmeasurable lesion according to RECIST version 1.1 (measurable lesion ≥20mm conventional CT scan and ≥10mm spiral CT scan, measurable lesion not receiving radiotherapy).
- The functions of the main organs are basically normal.
- Have not received radiotherapy, endocrine therapy, molecular targeted therapy, or surgery (except for procedures unrelated to antitumor therapy such as central venous catheterization) within 3 weeks prior to the start of the study, and have recovered from acute toxic effects of previous treatment (if surgery is available, the wound has fully healed).
- No peripheral neuropathy or grade I peripheral neurotoxicity.
- Fertile female subjects are required to use a medically approved contraceptive during study treatment and for at least 3 months after the last use of the study drug; The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
Exclusion Criteria:
- Stage II: patients with adjuvant/neoadjuvant use of paclitaxel but the interval from the end of taxol treatment to recurrence and metastasis is less than 6 months, or have received systemic anti-tumor therapy (chemotherapy, targeted therapy, etc.) in the late stage;
- Stage I: no systemic anti-tumor therapy (chemotherapy, targeted therapy, etc.) has been received in the advanced stage;
- Patients with known central nervous system metastasis or history of central nervous system metastasis prior to screening. For patients with clinically suspected central nervous system metastasis, enhanced CT or enhanced Magnetic Resonance Imaging (MRI) must be performed within 28 days before the first dose to rule out central nervous system metastasis.
- A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
- Persistent grade ≥1 adverse events due to previous treatment. The exception to this is hair loss or something the researchers believe should not be ruled out. Such cases should be clearly documented in the investigator's notes;
- Major surgery was performed within 3 weeks of the first course of trial treatment (except for minor outpatient surgery, such as placement of vascular access);
- Pregnant or lactating patients;
- Other malignancies within the previous 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma.
- Inability to swallow, chronic diarrhea and intestinal obstruction, there are multiple factors that affect drug use and absorption;
- There is a third space effusion that cannot be controlled by drainage or other methods (such as excessive pleural fluid and ascites);
- Participated in clinical trials of other antitumor drugs within 4 weeks before taking the study drug for the first time;
- long-term unhealed wounds or incomplete healing fractures;
- Patients with known HBV or HCV infection active phase or hepatitis B DNA≥500, or chronic phase with abnormal liver function;
- Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
- Malignant tumors within the past five years (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LAR
Coelomofacial androgen receptor
|
SG 10mg/kg d1, 8;SHR3680 240mg qd,3 weeks is a cycle
SG 10mg/kg d1, 8
|
Experimental: IM
Immunoregulatory type
|
SG 10mg/kg, d1, 8;SHR1210 200mg,d1,q3w;
SG 10mg/kg, d1, 8
|
Experimental: BLIS
Basal type and immunosuppressive type
|
SG 10mg/kg d1, 8;SHR3162,150mg,QD ,3 weeks is a cycle
Other Names:
SG 10mg/kg d1, 8
|
Experimental: MES
Interstitial type
|
SG 10mg/kg,d1, 8;BP102 15mg/kg,d1,3 weeks is a cycle
Other Names:
SG 10mg/kg d1, 8
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: max 6 months
|
time to progressive disease (according to RECIST1.1)
|
max 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: max 6 months
|
The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)
|
max 6 months
|
DOR
Time Frame: max 6 months
|
Duration of Overall Response.The date of the first assessed PR/CR (according to RECIST 1.1) to the date of the first assessed tumor progression (according to RECIST 1.1) or death from any cause.
|
max 6 months
|
OS
Time Frame: max 6 months
|
Overall survival
|
max 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2023
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
June 23, 2023
First Submitted That Met QC Criteria
June 23, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 23, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Future-Trop2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on TNBC - Triple-Negative Breast Cancer
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdRecruitingTriple Negative Breast Cancer (TNBC)India
-
Fudan UniversityRecruiting
-
Mridula George, MDRecruitingOCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast CancerTriple Negative Breast Cancer (TNBC)United States
-
Shanghai Jiaolian Drug Research and Development...Shanghai Pharmaceuticals Holding Co., LtdRecruitingTriple Negative Breast Cancer (TNBC)China
-
Beijing 302 HospitalRecruitingTNBC - Triple-Negative Breast CancerChina
-
Novartis PharmaceuticalsTerminatedTriple Negative Breast Cancer (TNBC)Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
-
Calithera Biosciences, IncCompletedTriple Negative Breast Cancer | TNBC - Triple-Negative Breast CancerUnited States
-
ImmunityBio, Inc.WithdrawnTriple Negative Breast Cancer (TNBC)United States
Clinical Trials on A1:SG with SHR3680
-
a2 Milk Company Ltd.CompletedLactose Intolerance
-
T-knife GmbHTerminatedAdvanced Solid TumorsGermany, Belgium, Spain, Netherlands, United Kingdom
-
University Hospital, LilleMinistry of Health, FranceRecruiting
-
Zagazig UniversityUnknown
-
Fudan UniversityRecruiting
-
Meshalkin Research Institute of Pathology of CirculationUnknownMitral Valve InsufficiencyRussian Federation
-
Fudan UniversityActive, not recruitingTNBC - Triple-Negative Breast CancerChina
-
Fudan UniversityRecruiting